ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism
Open accessThe DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index; 91 of the 188 sources its claims cite were checked for support.
Abstract
Sodium levothyroxine (LT4) as a monotherapy represents the mainstay of treatment of hypothyroidism, and its use has increased over time. Nevertheless, it faces several potential barriers in its ‘real life’ utilization, and hence its clinical effectiveness may be marred. This is suggested by the frequent situation of patients failing to reach the therapeutic goals of symptom relief and serum TSH control. Thus, an expert task force was approved by the Guidelines Board of the European Thyroid Association to examine the available data and to formulate recommendations based on the available evidence and the experts’ deduction. The task force provides a body of suggestions to optimize the levothyroxine treatment in monotherapy, considering the key point in the individualization of treatment. Furthermore, the nutritional, pharmacological and pathological factors, potentially leading to the increased need for levothyroxine, are discussed, with a specific focus on the use of liquid and softgel formulations of the hormone.
Overview
CoChat Summary
TL;DR
This ETA guideline provides recommendations to optimize levothyroxine sodium monotherapy in hypothyroidism, emphasizing individualized treatment and management of adherence, nutritional, pharmacological, and pathological interferences. It highlights liquid and softgel LT4 formulations for patients at risk of tablet malabsorption or altered gastric pH.
Key findings
- Almost half of LT4-treated primary hypothyroid patients worldwide appear under- or over-treated when serum TSH is used as the marker of adequate thyroid hormone status.
- In a cited absorption study, a free T4 increment at 3 h above 5.15 pmol/L had 97% sensitivity and 80% specificity for excluding true malabsorption.
- Coffee co-administration decreased the incremental rise in serum T4 by 36% in hypothyroid patients and 29% in healthy volunteers, and decreased peak T4 by 30% and 19%, respectively, while delaying T4 maximum serum level by 38 and 43 min.
- A cited meta-analysis found that switching from tablet to liquid LT4 produced a pooled mean TSH reduction of 4.23 mU/L (95% CI 3.69–4.77); the guideline also reports increased LT4 needs in celiac disease (+49%), lactose intolerance (median ~31% higher), ulcerative colitis (26% higher in 12/13 patients), and RYGB (+27%).
Methods
- An expert task force approved by the ETA Guidelines Board examined available data and formulated recommendations based on available evidence and expert deduction; the methodology is provided as Supplementary Material.
- Recommendations are graded by strength, quality of evidence using Ø symbols, and agreement votes, mostly 8/8.
- The paper is a narrative guideline synthesis covering LT4 pharmacology, adherence, timing, food and drug interactions, comorbidities, special populations, and tablet versus liquid/softgel formulations.
Limitations
- The paper states that special-situation statements are mainly expert opinion based due to limited peer-reviewed publications; it also notes no focused RCTs in elderly patients, no controlled trials for fertility-treatment clinical outcomes, sparse RCTs comparing formulations, and no prospective studies systematically comparing liquid gel with solid formulations for clinical outcomes.
- The paper states that most formulation-comparison studies were small, short, non-comparable, and at high risk of selection and performance bias.
- Evident from the text: many recommendations are weak or based on low-quality evidence, and several authors report industry ties (speaker honoraria, speaker fees, or consulting for Merck, Abbott, Berlin-Chemie, and Institut Biochimique SA), although the guideline itself received no specific funding.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
75 Valid · 3 Not valid · 67 Not checked · 13 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“A case series article reported some clinical evidence of the refractoriness of hypothyroidism due to improper storage of tablet levothyroxine (27).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > Issues about the drug
What the sources say
- Supportedcites [27] Benvenga, 2017, Refractory hypothyroidism due to improper storage of levothyroxine tablets, Front Endocrinol source
The Abstract (Objective and Results) describes eight patients with refractory hypothyroidism who stored levothyroxine tablets improperly. It reports that serum TSH normalized in all cases after patients were advised to store new tablets away from heat, light, and humidity, supporting the cited case-series claim. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Doses of levothyroxine of approximately 1.3–1.5 μg/kg/day were reported to be sufficient in control subjects positively devoid of comorbidity or drug interference (49).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > The search for a minimal effective dose > Minimal effective dose of LT4
What the sources say
- Supportedcites [49] Virili, 2022, Levothyroxine treatment and gastric juice pH in humans: the proof of concept, Endocrine source
In Patients and methods > Patients, the reference group reached target TSH on a mean levothyroxine dose of 1.27 µg/kg/day; the paper defined a requirement above 1.51 µg/kg/day as increased. The same section describes the reference group as lacking signs of malabsorption or dyspepsia, and the study excluded patients with specified illnesses or interfering drugs. Page numbers are not available in the supplied copy. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A randomized crossover trial in 201 older patients (60 years or older) did not detect any significant differences in the mean TSH levels between an hour before breakfast administration versus an hour after evening meal dosing regimen (43).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > The search for a minimal effective dose > Timing of treatment with LT4
What the sources say
- Supportedcites [43] de Mello, 2022, Evaluation of bedtime vs morning levothyroxine intake to control hypothyroidism in older patients: a pragmatic crossover randomized clinical trial, Front Med source
The Abstract (Materials and Methods) describes a randomized crossover trial of 201 participants aged at least 60, comparing levothyroxine 60 minutes before breakfast with 60 minutes after the last meal. The Results (Bedtime vs. Morning LT4 Intake) report no statistically significant difference in mean TSH between regimens (p = 0.107). (LLM, conf=0.94)
plainn = 201- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Some types of foods and dietary supplements have been reported to reduce LT4 absorption, including soy, coffee, calcium, and grapefruit (14, 46) (Table 1).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > The search for a minimal effective dose > Interference with food
What the sources say
- Supportedcites [14] Virili, 2019, Gastrointestinal malabsorption of thyroxine, Endocr Rev source
The Nutrients and food interference section reports interference from soy and coffee; the Drugs interference at gastric level section says calcium preparations reduce T4 bioavailability. The discussion of intestinal transporters says grapefruit components can reduce oral availability, although their effect on thyroxine exposure was minimal. The claim is appropriately framed as what has been reported, rather than as an equally strong effect for every item. (LLM, conf=0.88)
- Supportedcites [46] Wiesner, 2021, Levothyroxine interactions with food and dietary supplements – a systematic review, Pharmaceuticals source
The Conclusions report decreased LT4 absorption with soy products, coffee, and calcium supplements. Section 2.9 reports that grapefruit juice reduced LT4 exposure in a study, although the authors considered the interaction small. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In conclusion, the co-prescription of LT4 with several interacting drugs or supplements can frequently lead to decreased LT4 bioavailability, which may often be clinically relevant (84).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > Thyroxine interaction with drugs and polypharmacy > Drug interaction with LT4 absorption
What the sources say
- Supportedcites [84] Liu, 2023, Medications and food interfering with the bioavailability of levothyroxine: a systematic review, Ther Clin Risk Manag source
The Introduction reports that many medications alter LT4 bioavailability and that interactions can elevate TSH despite dose increases. The Conclusion states that many medications, foods, and beverages impair LT4 bioavailability and recommends clinical measures to manage the interactions. These passages support the claim’s qualified statement about potentially clinically relevant effects. (LLM, conf=0.90)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
104 more claims · 52 with their cited sources checked
Create a free account to see all 158 claims and to verify the 3 references still open.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 8
- The quote only partly states this claim. 1
Citations
Cites
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Self-citationJonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 1×
“In contrast to the consistent results reported in the above studies, the effect of sex, menopausal status, and the presence of the type 2 deiodinase gene ( DIO2 ) Thr92Ala polymorphism have not been conclusive (68).”
Self-citationChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Self-citationSurks, M. I., & Hollowell, J. G. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1499 · Cited by 750 · cited 2×
“There is robust evidence that serum TSH levels increase slightly with age, particularly after the age of 65 – 70 years (9, 74).”
InfluentialLazarus, J., Brown, R. S., Daumerie, C., Hubalewska-Dydejczyk, A., Negro, R., & Vaidya, B. (2014) · European Thyroid Journal · doi:10.1159/000362597 · Cited by 742
Comparison of drug adherence rates among patients with seven different medical conditions
Briesacher, B. A., Andrade, S. E., Fouayzi, H., & Chan, K. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.437 · Cited by 587 · cited 1×
“Despite WHO stating that the mean adherence rate for long-lasting treatments is about 50%, hypothyroidism treatment has been reported to be one of the clinical conditions for which there is better patient compliance (30).”
Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · cited 4×
“Indeed, several studies have demonstrated that patients with decreased gastric acid secretion, owed to the use of proton pump inhibitors (PPIs), may need higher LT4 doses to achieve target TSH levels, long-term PPI administration presenting a heightened risk in these cases (47, 78).”
InfluentialSelf-citationLevothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022552 · Cited by 307 · cited 2×
“Lean body mass is not the only variable to estimate the therapeutic post-thyroidectomy LT4 dose, owing to the disappearance of thyroidal contribution to circulating T3 (102).”
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
Drugs that suppress TSH or cause central hypothyroidism
Haugen, B. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.08.003 · Cited by 252 · cited 1×
“It is worth noting that serum TSH concentrations may be altered by the patient ’ s demographic characteristics and comorbidities, concomitant drug use, assay interference and so on (3, 4).”
Research works printed but not linked: 2
- Feldt-Rasmussen, 2020, Endotext [Internet]
- Feldt-Rasmussen, 2020, Laboratory measurement of thyroid-related hormones, proteins, and autoantibodies in serum, 868
Cited by
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease
Duntas, L. H., Pοlyzos, S. A., Gottwald‐Hostalek, U., Urgatz, B., & Yen, P. M. (2025) · Endocrine · doi:10.1007/s12020-025-04451-0 · Cited by 2
“Recent advancements in LT4 formulations and the use of precision dosing, patient-centered algorithms, a broader range of tablet strengths, and enhanced chemical stability support accurate dosing and maintenance of TSH-guided LT4 therapy [ 76 ].”
Self-citationPoisoning with Thyroid Hormones Used Illegally—Systematic Review
Skrzypiec‐Spring, M., Kujawa, K., Wietrzyk, A., Matuła, P., Materna, M., Michalska, W., Szumny, D., & Szeląg, A. (2025) · Pharmaceuticals · doi:10.3390/ph18121808 · Cited by 2
“According to the standard treatment for hypothyroidism, T4 is the drug [53].”
Scappaticcio, L., Martino, N. D., Ferrazzano, P., Nuzzo, M. D., Volatile, A., Caruso, P., Longo, M., Verde, M. L., Maiorino, M. I., FRANCISCIS, P. D., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.12.021 · Cited by 1
Self-citationWang, X., Shang, X., Li, Y. W., Lu, C., Shao, Y., Yang, D., Teng, W., & Shi, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1841255 · Cited by 5
Metadata
- Authors
- Centanni, M., Duntas, L., Feldt-Rasmussen, U., Koehrle, J., Peeters, R. P., Razvi, S., Trimboli, P., & Virili, C.
- Affiliations
- Sapienza University of Rome (IT)
- National and Kapodistrian University of Athens (GR)
- Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen University Hospital 3 , ,
- Institut für Experimentelle Endokrinologie, Charité Universitätsmedizin Berlin 4 , ,
- Erasmus MC (NL)
- Centre for Life (GB)
- Ente Ospedaliero Cantonale (CH)
- Corresponding author
- Centanni, Marco
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2025-07-07
- Volume
- 14
- Issue
- 4
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC12323320
- OpenAlex
- W4412070283
- Semantic Scholar
- 1c293e0f477cd2141c7e642a25f00dabc902f440
- Cited by
- 38
- References
- 132
- Citations by year
- 2026: 32 · 2025: 6
- FWCI
- 25.72
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- European Thyroid Journal (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- levothyroxine, hypothyroidism, monotherapy, personalized treatment, treatment optimization, barriers to treatment adherence, dietary factors, pharmacological factors, pathological factors
- MeSH terms
- Humans, Hypothyroidism, Thyrotropin, Thyroxine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism. https://app.cochat.ai/papers/10.1530/etj-25-0123
- The paper
- Centanni, M., Duntas, L., Feldt-Rasmussen, U., Koehrle, J., Peeters, R. P., Razvi, S., Trimboli, P., & Virili, C. (2025). ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism. European Thyroid Journal. https://doi.org/10.1530/etj-25-0123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.